Osteogenesis Imperfecta Market Set for Growth Through 2034 Driven by Emerging Sclerostin-Targeted Therapies - DelveInsight

DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Osteogenesis Imperfecta, historical and forecasted epidemiology, as well as the Osteogenesis Imperfecta therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

To know in detail about the Osteogenesis Imperfecta market outlook, drug uptake, treatment scenario and epidemiology trends, Click here: Osteogenesis Imperfecta Market Forecast
https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the Osteogenesis Imperfecta Market Report

• The Osteogenesis Imperfecta market size was valued at ~USD 30 million in 2023 and is anticipated to grow at a significant CAGR during the study period (2020-2034), reaching an estimated USD 500 million by 2034.
• The United States accounts for the largest Osteogenesis Imperfecta market size, at ~USD 20 million, compared to the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• There are currently no US FDA or Europe-approved treatments for osteogenesis imperfecta; treatment is directed toward preventing or controlling symptoms.
• There are at least 19 recognized forms of osteogenesis imperfecta, designated type I through type XIX, with overlapping characteristic features.
• In 2023, there were about 72,400 prevalent cases of osteogenesis imperfecta across the 7MM, with the US accounting for ~55% of cases, the EU4 and UK combined for ~35%, and Japan contributing ~10%.
• Osteogenesis imperfecta incidence varies globally, affecting approximately 1 in 10,000 to 20,000 births, with prevalence estimated at 6 to 7 per 100,000 individuals worldwide.
• In April 2024, Ultragenyx Pharmaceutical announced that enrollment is complete for the Phase III Orbit and Cosmic studies of setrusumab (UX143) in Osteogenesis Imperfecta. The Orbit study randomized 158 patients aged 5-25 years, while the Cosmic study enrolled 66 patients aged 2-7 years.
• Setrusumab (UX143) is expected to garner the largest market revenue among emerging therapies in the 7MM during the forecast period.
• The Osteogenesis Imperfecta pipeline is not particularly robust but includes potential drugs such as EVENITY (romosozumab) and Setrusumab (UX143), both currently in Phase III development for pediatric patients.
• Key Osteogenesis Imperfecta Companies: Amgen, UCB, Ultragenyx Pharmaceuticals, Mereo BioPharma, and others.

Get a Free Sample for the Osteogenesis Imperfecta Market Report:
https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Osteogenesis Imperfecta Overview

Osteogenesis imperfecta (OI), commonly referred to as brittle bone disease, is a genetic disorder primarily characterized by fragile bones that break easily, often with little or no trauma. The condition stems from abnormalities in the synthesis or processing of type I collagen, a protein crucial for bone strength and structure. Severity varies widely across the 19 recognized types, ranging from mild forms causing only a few fractures in a lifetime to severe types leading to multiple fractures even before birth. Other clinical manifestations include blue sclerae, short stature, hearing loss, and dental issues such as dentinogenesis imperfecta. The condition is inherited predominantly in an autosomal dominant pattern, and its presentation can significantly impact patients' quality of life.

Osteogenesis Imperfecta Diagnosis

Diagnosis typically involves clinical evaluation, family history assessment, and genetic testing. Healthcare providers look for characteristic signs such as frequent bone fractures, blue sclerae, and other skeletal deformities, while imaging studies like X-rays reveal bone density and structural abnormalities. Genetic testing can confirm diagnosis by identifying mutations in the COL1A1 or COL1A2 genes, responsible for most Osteogenesis Imperfecta cases. Early diagnosis is crucial for effective management and for preventing associated complications.

Download the report to understand which factors are driving Osteogenesis Imperfecta epidemiology trends @ Osteogenesis Imperfecta Epidemiology Forecast:
https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Osteogenesis Imperfecta Epidemiology

The epidemiology section provides insights into historical and forecasted trends in the 7MM. The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2036.

Osteogenesis Imperfecta Epidemiology Segmentation

• Prevalent Cases of Osteogenesis Imperfecta
• Diagnosed Cases of Osteogenesis Imperfecta
• Gene-specific Cases of Osteogenesis Imperfecta
• Type-specific Cases of Osteogenesis Imperfecta
• Total Treated Cases of Osteogenesis Imperfecta

Osteogenesis Imperfecta Treatment

Treatment for osteogenesis imperfecta focuses on preventing fractures and managing symptoms, as there is currently no cure. Bisphosphonates are commonly prescribed to strengthen bones and reduce fracture risk. Other interventions may include physical therapy, orthopedic surgery, and assistive devices to enhance mobility and independence. In severe cases, surgical procedures such as rodding may be performed to stabilize long bones and prevent deformities. Current treatment mostly comprises off-label therapies (bisphosphonates, denosumab), accounting for a market size of around USD 20 million in 2023.

Osteogenesis Imperfecta Drugs Uptake and Pipeline Development Activities

This section focuses on the uptake rate of potential Osteogenesis Imperfecta drugs expected to launch between 2024 and 2034, which depends on the competitive landscape, safety and efficacy data, and order of market entry. Key players evaluating novel therapies in pivotal and confirmatory trials must remain vigilant in selecting appropriate comparators to maximize their chances of regulatory approval, smooth launch, and rapid uptake.

Discover more about therapies set to grab major Osteogenesis Imperfecta market share @ Osteogenesis Imperfecta Treatment Market:
https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Osteogenesis Imperfecta Emerging Drugs and Key Companies

• EVENITY (romosozumab) - Amgen/UCB: A humanized monoclonal antibody (IgG2) that binds to and inhibits sclerostin, increasing bone formation while modestly decreasing bone resorption. Animal studies showed it stimulates new bone formation on trabecular and cortical bone surfaces, improving bone structure and strength. It is FDA-approved for osteoporosis in postmenopausal women at high fracture risk and is currently in Phase III for osteogenesis imperfecta in pediatric patients.
• Setrusumab (UX143) - Ultragenyx Pharmaceuticals/Mereo BioPharma: An investigational, fully human monoclonal antibody that inhibits sclerostin, a protein acting on a key bone-signaling pathway. By selectively binding to and inhibiting sclerostin, UX143 is designed to increase bone formation, density, and collagen production while reducing excessive bone resorption. It is currently in Phase III for osteogenesis imperfecta in pediatric patients and holds Orphan Drug Designation, Rare Pediatric Disease Designation, and Priority Medicines Program status.
• SAR439459 - Sanofi: A beta inhibitor administered intravenously, currently in Phase I.
• AGA2115 - Angitia: An intravenous therapy that neutralizes Dickkopf-1 (DKK1) and sclerostin, currently in Phase I, holding Rare Pediatric Disease Designation.
• Setrusumab vs. romosozumab target different pathways for Osteogenesis Imperfecta treatment: setrusumab focuses on bone formation, while romosozumab works by inhibiting sclerostin.

Osteogenesis Imperfecta Market Outlook

Key players including Ultragenyx Pharmaceuticals, Mereo BioPharma, Amgen, and UCB are evaluating their lead candidates across different stages of clinical development, aiming to bring novel products to the Osteogenesis Imperfecta treatment landscape.

Osteogenesis Imperfecta Competitive Landscape

The Osteogenesis Imperfecta market features a moderately competitive mix of multinational pharmaceutical companies, specialized biotechs, and emerging innovators working on both current treatment options and next-generation therapies. Established companies such as Amgen Inc., Novartis AG, Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., and Bristol-Myers Squibb are active in this space with bone-strengthening agents and supportive care products, while Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc lead efforts on novel targeted biologics such as sclerostin inhibitors for increasing bone density. Smaller biotech firms are also contributing through innovative approaches, including cell therapies and gene-focused research.
Competitive strategies include R&D investment in disease-modifying agents, strategic partnerships and licensing agreements, and expanding global distribution, all aimed at enhancing patient outcomes and capturing share in a growing rare disease segment. The landscape is shaped by innovation, regulatory incentives (such as orphan drug designations), and collaboration across industry and research institutions.

Key Osteogenesis Imperfecta Companies

• Amgen
• UCB
• Ultragenyx Pharmaceuticals
• Mereo BioPharma
• and others.

Osteogenesis Imperfecta Market Drivers

• Rising Prevalence and Diagnosis: Improved genetic testing, awareness, and early diagnosis are increasing patient identification, driving demand for targeted therapies and supportive care.
• Advancements in Therapeutic Development: Novel treatments such as bone-targeted therapies, gene therapy candidates, and anabolic agents are progressing through the pipeline, fueling market growth by offering disease-modifying potential.
• Growing Focus on Pediatric and Adult Care: Since Osteogenesis Imperfecta manifests early in life but requires lifelong management, increasing emphasis on long-term treatment strategies and quality of life drives sustained demand.
• Expansion of Orphan Drug Incentives and Regulatory Support: Orphan drug designations, accelerated approvals, and government incentives are encouraging investment in rare disease therapies, increasing R&D activity.
• Rising Awareness and Support Programs: Patient advocacy, educational campaigns, and better access to specialized care and diagnostic centers are improving disease management and expanding market opportunities.

Osteogenesis Imperfecta Market Barriers

• No approved disease-modifying therapies currently exist in the US or Europe, leaving treatment reliant on off-label bisphosphonates and denosumab.
• The heterogeneity of the disease, spanning 19 recognized types with overlapping features, complicates diagnosis, trial design, and treatment standardization.
• Rare disease status limits patient recruitment for clinical trials and constrains real-world data generation.
• Barriers to genetic testing remain high in several regions despite expert guidelines recommending mutation testing before therapy initiation.
• Country-specific accessibility and reimbursement challenges limit uptake of expensive emerging therapies once approved.

Scope of the Osteogenesis Imperfecta Market Report

• Study Period: 2020-2034
• Forecast Period: 2024-2034
• Coverage: 7MM
• Key Osteogenesis Imperfecta Companies: Amgen, UCB, Ultragenyx Pharmaceuticals, Mereo BioPharma, and others
• Key Osteogenesis Imperfecta Therapies: EVENITY (romosozumab), Setrusumab (UX143), SAR439459, AGA2115, and others
• Osteogenesis Imperfecta Market Size: Projected to reach USD 500 million by 2034
• Osteogenesis Imperfecta Therapeutic Assessment: Current marketed and emerging therapies
• Osteogenesis Imperfecta Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, and market entry strategies
• Osteogenesis Imperfecta Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.